Santen Pharmaceutical Co., Ltd. (4536.T) JPX

1,843.50

-20(-1.07%)

Updated at June 03 02:23PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Takeshi Ito	President, Chief Executive Officer & Representative Director	172M	1959
Shinichi Teramachi	Corporation Officer, Head of Sales and Head of Japan Sales & Marketing	0	N/A
Yoko Saiki	Corporate Officer & Chief Human Resources Officer	0	N/A
Kazuo Koshiji	Chief Financial Officer & Corporate Officer	0	N/A
Kenji Morishima	Corporate Officer & Head of China Product Development Department	0	N/A
Rie Nakajima	Chief Operating Officer, Corporate Officer & Director	0	1977
Kaori Itagaki	General Manager of Investor Relations Group	0	N/A
Daisuke Nakata	Chief Digital & Information Officer	0	N/A
Takahiro Morita	Global Head of Core Principle & Sustainability and Corporate Officer	0	N/A
Mika Masunari	Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer	0	N/A

Name

Title

Pay

Year Born

Takeshi Ito

President, Chief Executive Officer & Representative Director

172M

1959

Shinichi Teramachi

Corporation Officer, Head of Sales and Head of Japan Sales & Marketing

N/A

Yoko Saiki

Corporate Officer & Chief Human Resources Officer

N/A

Kazuo Koshiji

Chief Financial Officer & Corporate Officer

N/A

Kenji Morishima

Corporate Officer & Head of China Product Development Department

N/A

Rie Nakajima

Chief Operating Officer, Corporate Officer & Director

1977

Kaori Itagaki

General Manager of Investor Relations Group

N/A

Daisuke Nakata

Chief Digital & Information Officer

N/A

Takahiro Morita

Global Head of Core Principle & Sustainability and Corporate Officer

N/A

Mika Masunari

Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer

N/A

Description

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.